Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.31 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 2/20 | 0.30 |
| ▸ | CASP2 | P42575 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20980415 | 0.89 | — | — | |
| SCHEMBL20980404 | 0.78 | — | — | |
| SCHEMBL20980230 | 0.77 | ALB (0.38) | ALBHPSECNR2 | |
| SCHEMBL21465910 | 0.74 | ALB (0.39) | ALBMEN1KMT2AFAAHCASP2 | |
| SCHEMBL17742900 | 0.71 | ALDH1A1 (0.42) | ALBHPSEMEN1KMT2AFAAH | |
| SCHEMBL22375760 | 0.71 | ADRB2 (0.31) | CNR2 | |
| SCHEMBL17122488 | 0.71 | CASP2 (0.56) | FAAHCASP2 | |
| SCHEMBL18089125 | 0.70 | FAAH (0.46) | FAAHCASP2 | |
| SCHEMBL17881973 | 0.70 | CASP2 (0.42) | HPSEFAAHCASP2 | |
| SCHEMBL18880055 | 0.70 | CPB2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | GLP1R, GIPR, GRPR | ALB 4026/4885HPSE 1484/4885PLA2G10 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.